Xiaojiao Li

发表

Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor

D. Zhong, Hongbin Sun, Yifan Zhang, 2020, British journal of clinical pharmacology.

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Xiaojiao Li, Hong Zhang, Yue Hu, 2021, Expert opinion on investigational drugs.

S-amlodipine–bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy Chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study

J. Niu, Xiaojiao Li, Hong Zhang, 2019, Expert opinion on drug metabolism & toxicology.

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Limaprost in Healthy Chinese Subjects

Qi Zhang, Xiaojiao Li, Hong Zhang, 2015, Clinical Drug Investigation.

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Frontiers in Pharmacology.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS‐331007 in Healthy Chinese Subjects

J. Niu, Xiaojiao Li, Hong Zhang, 2019, Clinical pharmacology in drug development.

Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.

J. Niu, D. Brainard, Xiaojiao Li, 2018, Clinical therapeutics.

Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossover study in healthy Chinese male subjects.

Haiyan Chen, Qi Zhang, Xiaojiao Li, 2013, Clinical therapeutics.

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

J. Niu, D. Zhong, Wei Li, 2018, Front. Pharmacol..

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

Z. Ning, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus

Xiaojiao Li, Hong Zhang, Yan-hua Ding, 2021, Clinical pharmacology in drug development.

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects

Qi Zhang, Xiaojiao Li, Hong Zhang, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly

Shiping Ma, Hushan Wang, Xiaojiao Li, 2021, Frontiers in Pharmacology.

Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Expert opinion on investigational drugs.

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects

Xiaojiao Li, Hong Zhang, Haijing Wei, 2018, Cancer Chemotherapy and Pharmacology.

Comparison of the Pharmacokinetics of Generic Versus Branded Obeticholic Acid in a Chinese Population: Effects of Food and Sex

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Clinical pharmacology in drug development.

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Shiping Ma, Chengluan Xuan, Xiaojiao Li, 2022, Annals of medicine.

Autophagy Induced by ROS Aggravates Testis Oxidative Damage in Diabetes via Breaking the Feedforward Loop Linking p62 and Nrf2

Dongsheng Xu, Xiaojiao Li, Yuanyuan Tian, 2020, Oxidative medicine and cellular longevity.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

Xiaojiao Li, Yanhua Ding, Min Wu, 2021, Cancer Chemotherapy and Pharmacology.

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers

Xiaojiao Li, Yanhua Ding, Min Wu, 2021, Expert opinion on drug metabolism & toxicology.

Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, CNS Drugs.

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Pharmacology research & perspectives.

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial

J. Niu, Xiaojiao Li, Yanhua Ding, 2022, Antimicrobial agents and chemotherapy.

Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

J. Niu, Xiaojiao Li, Hong Zhang, 2021, Expert opinion on investigational drugs.

The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability

Ting Xu, Xiaojiao Li, Hong Zhang, 2022, Expert opinion on investigational drugs.

Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects

J. Niu, Xiaojiao Li, Hong Zhang, 2017, Hepatology International.

Randomised clinical trial: safety, efficacy and pharmacokinetics of HS‐10234 versus tenofovir for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Alimentary Pharmacology and Therapeutics.

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

X. Yang, Xiaojiao Li, Hong Zhang, 2022, BioDrugs.

Multiple dose study of GLS4JHS, interfering with the assembly of hepatitis B virus core particles, in patients infected with hepatitis B virus

J. Niu, Yitao Ding, Haiying Zhang, 2017 .

Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN&agr;2a for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2017, British journal of clinical pharmacology.

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Frontiers in Pharmacology.

Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2019, Antiviral research.

Effect of moderate activity on liver function and serum lipid level in healthy subjects during the phase I clinical trial

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Expert opinion on drug metabolism & toxicology.

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-Deficiency Anemia.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Annals of medicine.

A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Expert Opinion on Biological Therapy.

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Frontiers in Pharmacology.

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

QUAN LIU, J. Niu, Xiaojiao Li, 2020, Frontiers in Pharmacology.

Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and safety profiles of novel diethylstilbestrol orally dissolving film in comparison with diethylstilbestrol capsules in healthy Chinese male subjects.

Qi Zhang, Xiaojiao Li, Hong Zhang, 2014, International journal of clinical pharmacology and therapeutics.

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Antiviral research.

Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Expert Opinion on Investigational Drugs.

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Huanming Chen, Hui Lu, J. Niu, 2023, BMC Medicine.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects

Qi Zhang, Xiaojiao Li, Hong Zhang, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Frontiers in Pharmacology.

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Expert opinion on investigational drugs.

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2023, Nature communications.

Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects

Yingjie Guo, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.